Tirtha Chakraborty

A Human Genetics Framework for De-risking Gene Editing Targets for Hematopoietic Cell and Gene Therapy

The paper develops a proteogenomic framework to identify dispensable genes for safer gene editing in hematopoietic therapies, identifying 237 candidates including LY75.

Cutting Through the Artifacts: Dissecting gRNA Impurities with FUSS-seq

The paper identifies sequencing artifacts in gRNA purity assessment and introduces FUSS-seq to reduce them, improving accuracy for CRISPR-based therapeutics.

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML Therapy

This study evaluates ADGRE2 as an AML target, showing efficient gene editing in HSPCs to protect against myelotoxicity and developing ADGRE2-specific CAR T cells for therapy.

A resource and computational approach for quantifying gene editing allelism at single-cell resolution

The paper constructs a single-cell DNA sequencing atlas and introduces GUMM, a computational workflow, to accurately infer gene editing allelism despite technical artifacts.